Zhejiang Barty Medical Technology Co., Ltd’s Post

👏 Congratulations to Hengrui Pharma Co.,Ltd and Dr. Jens Bitsch Norhave PhD! Recently Dr. Jens Bitsch-Norhave has joined Hengrui as #VicePresident, Global Head of #CorporateDevelopment. Jens obtained a Master's degree in #Bioengineering and a Ph.D. in #Neuropharmacology from the #UniversityofCopenhagen in Denmark, and he is also pursuing an MBA at the same institution. During his 19-year tenure at Johnson & Johnson, Jens was primarily engaged in #BusinessDevelopment (#BD) affairs, successfully leading and completing numerous transactions covering R&D, commercial, and public health sectors, accumulating a wealth of professional experience. In recent years, Hengrui Pharmaceuticals has been increasing its investment in BD operations, especially through a "#newco" project, which not only secured a 19.9% equity stake in the new company but also a $100 million upfront payment and potential future sales royalties in the billions of dollars. Jens' joining marks the first time Hengrui's BD business has been led by a non-Chinese expert, indicating a clearer strategic direction for Hengrui's #globaldevelopment, focusing on BD cooperation rather than internal establishment. Inside sources say that Jens enjoys a high reputation in the U.S. BD circle and has been in contact with several of Hengrui's BD projects even before officially taking up his position. Industry insiders believe that Jens' addition is an important step for Hengrui to increase its overseas BD efforts, further promoting its internationalization process. #DrugTimes #ChinaPharma #WorldBDDay #globalization

Exploring New Horizons in Project Excellence! We at TUNECT CRO were excited to return to Asia for BIO KOREA 2024 in Seoul, a leading event in the bio-health sector. Anastasia, our esteemed Business Development Manager, represented us, enhancing our network and reinforcing partnerships that are vital to our growth and operational excellence. The dynamism and collaborative spirit at BIO KOREA were nothing short of electrifying! For potential clients and decision-makers, it's crucial to consider the Total Value Ownership that TUNECT brings to your projects. Our focus extends beyond cost to encompass overall value, ensuring alignment with your business goals through high-quality services, innovative solutions, and robust project management. We're not just a vendor; we are your strategic partner, committed to boosting the efficiency and effectiveness of your clinical trials through: 1. Advanced Data Management and Clinical Programming: We guarantee the integrity and traceability of data throughout the trial process, which is vital for regulatory approval and market success. 2. Experienced Professionals: Our team comprises highly skilled individuals with extensive knowledge and proficiency in navigating complex clinical environments. 3. Stringent Regulatory Compliance: We possess a profound understanding of global regulatory landscapes, significantly mitigating compliance risks. 4. Transparent Cost Management: Our pricing models are clear and straightforward, with no hidden fees, promoting budget predictability and stability. 5. Strategic Collaboration: We customize our services to meet your project's specific needs, focusing on sustainable and long-term success. We’re eager to demonstrate how our deep commitment to TVO can make a significant difference in your clinical trials. Let’s explore how we can bring transformative solutions to your projects! HiRO - Harvest Integrated Research Organization ICON plc #BIOKOREA2024 #BiotechIndustry #PharmaceuticalResearch #GlobalHealth #TUNECT #CRO #ClinicalTrials #TVO"

Indonesia is making significant strides in the medical device manufacturing industry! According to projections, the market is set to grow, reaching USD 2.71 billion by 2028.📈 As Indonesia strides in medical device manufacturing, now is the perfect moment to explore and capitalize on this sector. Ready to seize these opportunities? 🤔 Download our FREE detailed guide on doing business in Indonesia and uncover the potential that awaits you: https://lnkd.in/gFM7U9GX #InCorpIndonesia #MedicalDevice Vidvant Brahmantyo Daris Salam Pandu Biasramadhan

Industry 4.0 has brought significant changes in almost all sectors, including Biotechnology and the Medical world. Technological advancements in Industry 4.0 have made a huge impact in the provision of better Medical services, increased efficiency, and the development of innovative therapies. In the medical industry, the most important thing is that there are no mistakes. In a production to minimize these errors is to use robots in drug factories or other medical equipment. This is what makes the Biotechnology and Medical Industry very likely in the era of the Industrial Revolution 4.0. Jababeka saw this opportunity and created a new cluster with the name Biotech & Medical Cluster which is expected to help the Biotech & Medical Industry in Indonesia. Further information: Mobile / WA : 0812-8309-0900 www.jababeka.com Follow our Media Social : Instagram : @jababekaindustrialestate Facebook Page : @jababekaindustrialestate #jababeka #jababekaindustrialcluster #jababekaindustrialestate #jedihub #jababekaecommercedigitalhub #jababekaecommerceindustrialpark #ecommerceindustrialpark #ecommercehub #digitalhub #startupcluster #jababekabiotechcluster #biotechcluster #jababekahalalcluster #halalcluster #indonesia #singapore #malaysia #japan #southkorea #propertyinvestment #realestate Rudy Subrata

Hi 🙋♂️ #MedicaldeviceManufacture #MedicaldeviceProfessionals Visiting PHC Holdings Corporation's manufacturing site in Cikarang recently was an incredible experience, thanks to pak #Fiki & pak #faqih, Engaging in discussions about R&D, Downstream Manufacturing, Marketing & Sales in the Indonesian Healthcare Market, and PHC's dedication to producing high-quality Medical Devices and In-vitro Diagnostics domestically was inspiring!✨️ The Health Law's emphasis on the independence of Medical Devices is admirable. Prioritizing domestically produced Medical Devices for national health resilience and progress is a noble endeavor. It's evident that strengthening the integrated upstream-downstream supply chain governance and promoting the use of domestic raw materials by domestic industries is crucial for the industry's growth and the nation's health resilience. RnD indeed plays a critical role in the production of medical devices. We're grateful that the Indonesian government provides 300% RnD incentives (PMK 153/2020), although it is still lower than the high rate of return on investment (ROI) of medical research in Australia which reaches 400%. It's time for RnD, like institutions #BRIN, #IMERI, and #FTUI to collaborate with domestic medical device manufacturers and provide solutions. The Ministry of Health's initiatives to provide medical equipment in referral hospitals and Puskesmas throughout Indonesia are commendable and present significant opportunities for the global brand of medical devices to collaborate through foreign direct investment or contract manufacturing with the Domestic Medical Device Industry for Strengthening Primary Health Services in Indonesia (#SOPHI) and Strengthening the Indonesian Public Laboratory System (#InPULS). Are you ready to seize new opportunities and expand your Medical Devices network? Don't hesitate to contact Syifa - VP International Relations at +6287886111348 Azila - Manager +62896 52275526 You can also reach out directly to PT. Inspiry Indonesia Konsultan at +6221 22178061, +62877 6777 1778 or send an email to inspirya@inspiry.asia For more information please access👇 www.inspiryconsultant.com You can also watch INSPIRYTV for more information.👇 https://lnkd.in/g3_MvcXd Please explore our resources available to you, your journey to success in the Indonesian healthcare - Medical Device market starts here. Cheers to new adventures! 🙋🫡 Tagging permission 🙏 Lifotronic Zybio Southeast Asia Mindray Sysmex Asia Pacific NIHON KOHDEN PTE LTD HORIBA Endrajaya Tjen HKBio COSMED Fapon Comen Medical Device Manufacturing Medical Device Manufacturers Association (MDMA) Yus Rusdian Akhmad Prihatanto A. Hendro Witjaksono ACOMA Medical Imaging, Inc. SRI INTAN PERKASA Satrija Tawada elly mustrianita Accuray Imam Subagyo Kharisma Hidayat Hamzah Dimas Raihan F. SANSICO MEDICA Adrian Susanto PT. Gratia Jaya Mulya Rizki Utomo #contractmanufacturing #OEM #ODM #JagonyaKonsultanAlkes

Here are some highlights from the recent Intraceuticals Global Proprietary Oxygen Treatment Skill Contest 2024 China Region Final. Meticulously organized by the Intraceuticals Asia team and held at the exquisite Yuluxe Sheshan, Shanghai, a Tribute Portfolio Hotel, this event showcased our clinic partner's talent, innovation, and dedication to skincare excellence.   As the competition unfolded, the competitors had an opportunity to demonstrate their mastery of the craft and their deep understanding of Intraceuticals' cutting-edge treatments. Meanwhile, the judges, renowned experts in the field, offered insightful comments and critiques, recognizing the standard of technical proficiency and the creativity and ingenuity displayed by each contestant.   Intraceuticals continues to set the standard for excellence in skincare, and events like these reaffirm their commitment to innovation and education within the industry. #Intraceuticals #IntraceuticalsAsia 

Here's why Indonesia 🇮🇩 , right now, is a viable location for medical device registration. The country's growing middle class and the introduction of universal healthcare have driven demand across the sector, from hospitals and pharmaceuticals to medical devices. With the world's largest universal healthcare programme, the JKN, covering over 200 million people, Indonesia offers a vast and lucrative market. Standard Chartered Bank projects Indonesia's economy to grow significantly, from US$4.2 trillion in 2020 to US$10.1 trillion by 2030 🔥 , positioning it as the world's fourth-largest economy in terms of purchasing power parity. Additionally, its strategic position as a viable China+1 investment destination make it an attractive option for healthcare investors looking to diversify and expand their operations.

Agree. The improvements made to Indonesia's Universal Healthcare coverage and medical device regulations to international standards has made it more attractive for foreign medical device companies to invest in Indonesia. However, like any market you need to find the right partner to help you navigate away from the potholes and unnecessary red tape to achieve your business goals.

#LegendCapital It has been an honor for Legend Capital君联资本 to co-organize the Indonesia-China Healthcare and Biotech Investment Forum in Jakarta with the Indonesian Ministry of Health (MOH) and the Indonesian Food and Drug Authority (BPOM) at the end of January this year.   The event has attracted a good number of leading companies from China and Indonesia to attend. During the Forum, participants have exchanged views and discussed the direction and opportunities for the development of healthcare and biotech in China and Indonesia.   Based on the consensus of “Wider range, Openness, and Win-win”, a deepening of cooperation in medical devices, innovative pharmaceuticals, clinical CROs and digital healthcare services is foreseeable between China and Indonesia. It is expected that with the efforts of MOH, BPOM, medical enterprises, and investment institutions, more Chinese medical enterprises and investment institutions will invest and develop in Indonesia, so as to combine innovative technologies, advanced concepts, and China’s experience with Indonesia's national conditions, promoting the healthy development of Indonesia's healthcare. #China #Indonesia #MOH #BPOM #Openness #Innovation #MedicalDevices #Pharmaceuticals #CROs #Healthcare #Biotech #Investment #Forum #Cooperation Click here for more details about the Forum: https://lnkd.in/gBVykTBW

Noul, a biomedical startup, has achieved a significant milestone by obtaining the Imported Medical Device Distribution Permit from the Ministry of Health Republic of Indonesia. This approval is a landmark for Noul, marking the first marketing authorization for its AI-based blood analysis products in ASEAN countries. Currently, Noul holds marketing approvals in Indonesia, Malaysia, and the Philippines, with certifications in progress for Thailand and Vietnam. This achievement comes amid strengthened medical device regulations in the ASEAN region, where Indonesia follows the ASEAN Medical Device Directive (AMDD) to ensure compliance with international standards. Kim Tae-hwan, Chief Business Officer of Noul, highlighted Indonesia's strategic importance by noting its population of 280 million and an annual economic growth rate surpassing 5%. He pointed out that Indonesia represents 36% of the ASEAN economy and is swiftly moving toward digital healthcare, with a remote healthcare market growth rate exceeding 600%. Noul anticipates that its miLab products will flourish in this dynamic landscape. Source: News1 #HealthcareInnovation #ASEAN #MedicalDevices #DigitalHealth #GlobalExpansion #BloodAnalysis #MedTech #HealthTech #RemoteHealthcare #SoutheastAsia #RegulatoryApproval